Description:
Looking for experience with the following: integrated work cells, schedule/run bench data to confirm validated SOPs, data analysis capture, report data to internal/external clients
Working on the Assay Development/Screening team developing assays in plates, generate large data sets/metadata, insights from the data, operationalize the workflow on a cadence/routine (lean training)
Experience developing and/or executing assays in a high-throughput setting.
Experience with mammalian cell transfection, flow cytometry, and/or high-content screening is a plus.
Plan and execute high-throughput screens and interpret experimental results to plan the next steps for the project.
Additional Skills & Qualifications:
BS or MS in biology, biochemistry, bioengineering, pharmacology, or equivalent; 3-4 years of experience in an industry laboratory setting working as part of a multi-disciplinary team are preferred.
Experience with basic biology laboratory techniques and equipment, including plate readers and liquid handlers
Diversity, Equity & Inclusion
At Actalent, diversity and inclusion are a bridge towards the equity and success of our people. DE&I are embedded into our culture through:
Hiring diverse talent
Maintaining an inclusive environment through persistent self-reflection
Building a culture of care, engagement, and recognition with clear outcomes
Ensuring growth opportunities for our people
Actalent is an equal opportunity employer.
About Actalent
Actalent connects passion with purpose. We help visionary companies advance their engineering and science initiatives through access to specialized experts that drive scale, innovation, and speed to market. With a network of almost 30,000 engineering and sciences consultants and more than 4,500 clients across the U.S., Canada, Asia, and Europe, Actalent serves many of the Fortune 500. An operating company of Allegis Group, the global leader in talent solutions, Actalent launched as a new specialized engineering and sciences services and workforce solutions brand in 2021.